GE Healthcare has acquired Asymptote Ltd., specialists in cryochain technology for sensitive cellular therapies. Asymptote’s suite of cryochain hardware, software and consumables are designed to maintain the potency of cellular therapies enabling ultra-low temperature freezing during production, all the way to thawing at the clinic prior to administering to patients. The acquisition expands products and services for cell therapy production.    As the cell therapy market develops, demand for ma...